Clinical trial
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
NCT01280695 is registered in ClinicalTrials.gov with Metabolic Solutions Development Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
- Lead sponsor
- Metabolic Solutions Development Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- June 30, 2011
- Enrollment
- 129 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.